[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
News From the Centers for Disease Control and Prevention
October 6, 1999

Availability of Hepatitis B Vaccine That Does Not Contain Thimerosal as a Preservative

JAMA. 1999;282(13):1219-1220. doi:10.1001/jama.282.13.1219

MMWR. 1999;48:780-782

On August 27, 1999, Merck Vaccine Division* (Merck & Co., Inc., West Point, Pennsylvania) received approval from the Food and Drug Administration (FDA) of a supplement to Merck's license application to include the manufacture of single-antigen preservative-free hepatitis B vaccine (Recombivax HB®, Pediatric); distribution is expected to begin September 13, 1999. In addition, SmithKline Beecham Biologicals (SmithKline Beecham, Philadelphia, Pennsylvania), expects to make single-antigen preservative-free hepatitis B vaccine (Engerix-B®, Pediatric) available in the near future. Further product information will be provided when it becomes available. Product packaging and labels will indicate that these vaccines do not contain preservative.

×